The Latest Breaking News from BioNTech

The mRNA vaccine story during the COVID-19 pandemic placed an extraordinary premium on altruism on the part of scientists

Katalin Karikó, now a vice-president at BioNTech, saw her research undermined for years before the 2005 breakthrough that led to the COVID-19 vaccine.

Moderna's potential beyond COVID-19 is underappreciated, says analyst Eliana Merle, who upgraded the stock to Buy

Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, Moderna (MRNA) and BioNTech (BNTX), is a more favorable investment choice in the current uncertain economic climate. Keep reading to find out.

The immunologist who runs Scancell is trialling novel treatments to attack tumours, as well as needle-free Covid jabs

Here’s a look at the status of mRNA technology's application in cancer and when it might reach patients.

Top U.N. officials and health industry leaders are trying to tackle an alarming surge in tuberculosis, which is now killing more people worldwide than COVID-19 or AIDS

Pfizer Inc and BioNTech's new proposal to the European Union, amid a glut of COVID-19 shots, includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled doses, the Financial Times reported on Sunday. The revised contract would allow…

Experts hope new vaccines will be ready by end of decade